Pfizer Inc, Cambridge, MA, United States
Disclosure information not submitted.
4D-05 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
Monday, August 25, 20255:15 PM - 5:30 PM ET
